Notizie
Per il Corso di Scienze Mediche del Corso di Laurea Magistrale in Odontoiatria e Protesi Dentaria, è stata attivata la piattaforma Google Classroom:
Modalità per accedere alla Classroom:
1. accedi a https://classroom.google.com
2. Google classroom
3. Accedi digitando codice corso: eknv3ym
4. per accedere ai documenti caricati accedere al drive - Classroom - SCIENZE MEDICHE per ODONTO
Per il Corso di Artificial Intelligence, Machine Learning, Big Data del Corso di Laurea Magistrale in Medicina e Chirurgia HT, è stata attivata la piattaforma Google Classroom:
Modalità per accedere alla Classroom:
1. accedi a https://classroom.google.com
2. Google classroom
3. Accedi digitando codice corso: bshq2w2
Per il modulo di Medicina Interna, i materiali didattici sono disponibili su elearning Sapienza:
https://elearning.uniroma1.it/course/view.php?id=16424
Orari di ricevimento
Clinica Medica 2. Su appuntamento per email.
Curriculum
Giorgio GRANI
Office address: Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma, Viale del Policlinico 155 00161 Rome (Italy)
E-mail address: giorgio.grani@uniroma1.it
CURRENT POSITION
Giorgio Grani is an Associate Professor of Internal Medicine (SSD MED/09) at the Department of Translational and Precision Medicine, Sapienza University of Rome. He is a Medical Doctor specialized in Endocrinology and Metabolic Diseases and serves as Attending Physician at the Policlinico Umberto I University Hospital in Rome.
PRIOR APPOINTMENTS SCIENTIFIC QUALIFICATIONS
01/03/2022 – 28/02/2025: Tenure-track Assistant Professor (Ricercatore a tempo determinato di tipo B) of InternalMedicine (MED/09; 06/B1), Dept. of Translational and Precision Medicine, Sapienza University of Rome
15/03/2019 - 28/02/2022: Assistant Professor (Ricercatore a tempo determinato di tipo A), Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma
12/11/2020 - 12/11/2029: National scientific qualification as associate professor of Internal Medicine (06/B1)
PUBLICATIONS
Articles: 116
Sum of the times cited: 3991 (Scopus)
H-index: 35 (Scopus)
EDUCATION
27/02/2009: Degree (summa cum laude) in Medicine and Surgery at Sapienza Università di Roma
21/05/2015: Clinical specialist diploma (equivalent to Board Certification) in Endocrinology and Metabolism atSapienza Università di Roma
26/02/2019: PhD degree in Biotechnologies in Clinical Medicine at Sapienza Università di Roma
AWARDS AND PRIZES
Maccaroni Thesis Prize awarded by the Regional Medical Council (2010)
SIUMB Young Member Award (2012)
European Thyroid Association Travel Grant (2012)
European Society of Endocrinology Travel Grant (2013)
European Thyroid Association Travel Award Grant (2014)
SIUMB Young Member Award (2014)
Italian Thyroid Association Best Poster Prize (2016)
European Thyroid Association Travel Award Grant (2017)
American Thyroid Association Trainee Grant Program (2018)
Marco Attard Prize (2018) awarded by the AME Onlus and ITCO Foundation
Biagio Agnes Check-up Health Italy Prize (2019)
American Thyroid Association Trainee Grant (2019)
SIUMB Young Investigator Prize (2019)
Domenico Salvatore Prize, granted by the Cenacolo della Cultura e della Scienza (2021)
RESEARCH PROJECTS AND GRANTS
Intramural grants:
Sapienza University Scientific Equipment Grant (2019)
Deep learning to improve the sonographic classification of thyroid nodules (2019)
Evaluating the role of molecular signatures of thyroid cancer in the estimation of recurrence risk using a real-world database (2020)
Predicting molecular alterations using radiomics-derived data from sonographic images of thyroid nodules (2021)
Extramural grants:
Cesare Serono Foundation Research Grant in Reproductive Medicine (2009-10)
European Thyroid Association Research Grant (2018)
Google Cloud Platform Research Program Credits (2019)
DAIbetes - Federated virtual twins for privacy-preserving personalised outcome prediction of type 2 diabetes treatment (HORIZON-HLTH-2023-TOOL-05 Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management) (01/01/2024-31/12/2029)
INNOVATION AND TECHNOLOGY TRANSFER
Patent No.102019000024009: New method for the diagnosis of a thyroid tumor and related kit . Filed on December13, 2019. Issued November 29, 2021. Inventors: FILETTI Sebastiano, DURANTE Cosimo, VERRIENTI Antonella,SPONZIELLO Marialuisa, GRANI Giorgio
COMMITTEES
2019-Present: Member of the International Thyroid Nodule Working Group (ITNWG) Task Force for establishing an Universal Thyroid Imaging Reporting And Data System (TIRADS)
EDITORIAL ACTIVITIES
Associate Editor 2020-2023; Endocrine (SpringerNature, ISSN 1355-008X)
Editorial Board Member 2022-2023; Thyroid (Official Journal of the American Thyroid Association)
Associate Editor 2022-2023; Clinical Thyroidology (Official Journal of the American Thyroid Association)
Peer-reviewer for several journals in the field of; clinical medicine (e.g., British Medical Journal); endocrinology (e.g.,Journal of Clinical Endocrinology and Metabolism, European Journal of Endocrinology); pathology (e.g., DiagnosticCytopathology); radiology (e.g., European Radiology, Korean Journal of Radiology); oncology (Cancer Investigation,Cancer Medicine, BMC Cancer);
CLINICAL RESEARCH ACTIVITIES
Subinvestigator, Serena Study (NCT01465867)
Subinvestigator, ELITE study (IRCCS National Oncology Institute, Milan)
Subinvestigator, EISAI E7080-G000-211 (A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will ProvideComparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile, NCT02702388)
Subinvestigator, EISAI E7080-M000-213 (An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for theTreatment of Anaplastic Thyroid Cancer, NCT02657369)
Subinvestigator, EXELIXIS XL 184-401 (A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients, NCT01896479)
Subinvestigator, EXELIXIS XL 184-311 (A Study of Cabozantinib Compared With Placebo in Subjects WithRadioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy,NCT03690388)
Subinvestigator, SOUL (A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes, NCT03914326)